You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 9,241,980

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,241,980

Title:	Treatment of ophthalmic conditions
Abstract:	Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The present invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system.
Inventor(s):	Osio Sancho; Alberto (Mexico, MX)
Assignee:	Osio Corporation (Coronado, CA)
Application Number:	14/532,851
Patent Claims:	1. An ophthalmic pharmaceutical composition comprising: (1) hyaluronidase in a range of about 0.01% to about 10% (weight percent); (2) collagenase in a range of about 0.01% to about 10% (weight percent), wherein the collagenase is not matrix metalloproteinase 1 or matrix metalloproteinase 2; and (3) a vehicle; wherein the composition is suitable for administration to the eye of a patient. 2. The pharmaceutical composition of claim 1, wherein the composition is hypertonic. 3. The pharmaceutical composition of claim 1, wherein the composition is hypotonic. 4. The pharmaceutical composition of claim 1, wherein the composition is a liquid. 5. The pharmaceutical composition of claim 1, wherein the composition is a gel. 6. The pharmaceutical composition of claim 1, wherein the composition comprises a polymer as a vehicle. 7. The pharmaceutical composition of claim 6, wherein the polymer is selected from the group consisting of methylcellulose, cellulose, polyethylene glycol, and polyvinyl alcohol. 8. The pharmaceutical composition of claim 1 comprising hyaluronidase in the range of about 0.1% to about 5% (weight percent); and collagenase in the range of about 0.1% to about 6% (weight percent). 9. The pharmaceutical composition of claim 1, wherein the composition comprises at least one additional agent selected from the group consisting of other enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, anti-viral agents, anti-fungal agents, lubricants, and anti-inflammatory agents. 10. The pharmaceutical composition of claim 1, wherein the composition comprises at least two additional agents selected from the group consisting of other enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, anti-viral agents, anti-fungal agents, lubricants, and anti-inflammatory agents. 11. The pharmaceutical composition of claim 1, wherein the composition comprises at least three additional agents selected from the group consisting of other enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, anti-viral agents, anti-fungal agents, lubricants, and anti-inflammatory agents. 12. The pharmaceutical composition of claim 1, wherein the composition is a semi-solid gel. 13. The pharmaceutical composition of claim 1, wherein the composition is in the form of a spray. 14. The pharmaceutical composition of claim 1, consisting essentially of hyaluronidase and collagenase. 15. A kit comprising a contact lens and a pharmaceutical composition of claim 1. 16. The kit of claim 15 further comprising instructional materials. 17. The kit of claim 15 further comprising contact lens cleaning supplies. 18. The kit of claim 15, wherein the contact lens is gas permeable. 19. The kit of claim 15, wherein the contact lens is a molding contact lens.

Details for Patent 9,241,980

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004	⤷ Try a Trial	2023-12-19
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004	⤷ Try a Trial	2023-12-19
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004	⤷ Try a Trial	2023-12-19
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005	⤷ Try a Trial	2023-12-19
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965	⤷ Try a Trial	2023-12-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.